- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01090804
The Effectiveness of BreatheMAX Breathing Device on Secretion Clearance (ESMOSC)
March 22, 2010 updated by: Khon Kaen University
The Effectiveness of BreatheMAX Breathing Device on Airway Secretion Clearance in Patients With Ventilatory Dependence
The purpose of this study is to determined effects of BreatheMAX on secretion clearance.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
14
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Khon Kaen
-
Muang, Khon Kaen, Thailand, 40002
- Recruiting
- Pulmonary research room of physical therapy department, Faculty of associated medical sciences, Khon Kaen University
-
Contact:
- Sujittra Kluayhomthong, Bachelor
- Phone Number: 668-139-0647
- Email: rabbit_tigger@hotmail.com
-
Contact:
- Chulee CU Jones, Philosophy
- Phone Number: 664-320-2399
- Email: chujones46@yahoo.co.uk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 85 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- One sign of secretion accumulation in bronchi
- Stable cardiopulmonary function
- Good consciousness and good co-operation
Exclusion Criteria:
- Massive hemoptysis
- Pneumothorax (untreated)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: breathing exercise
BreatheMAX breathing device is Water pressure Threshold Bottle.
The level of water in the cylinder determines the load for treatment.
In the treatment using 20% PNIP (Peak negative inspiratory pressure) was performed with 6-10 breaths/set; 10 set/day
|
secretion clearance, breathing exercise
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
secretion wet weight (gram)
Time Frame: Three hours before, ten hours after treatment and night-time (02.00-07.00 am.)
|
Airway mucus secretion was collected for three hours before and ten hours after treatment based on an auditory airway secretion sound and collected again at 02.00-07.00
am.The mucus secretion was collected by sterile suctioning technique via tracheostomy tube without adding any saline or sterile water.
|
Three hours before, ten hours after treatment and night-time (02.00-07.00 am.)
|
|
viscosity of secretion
Time Frame: Three hours before and after treatment
|
The secretion were collected in three hours before and after treatment, It were measured viscosity by First The mucus was gently homogenized by tissue grinder 5 ml (Cw11-205, Cowie, UK) for six minute at 37 degree celsius Second using Micro-Oswald viscometers with a capillary diameter of 0.77 mm for viscosity measure at same temperature in each sample(before and after).
|
Three hours before and after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart rate (beat/min)
Time Frame: Before, during breathing exercise with device and immediate after treatment
|
Heart rate was monitored before, during and immediate after breathing exercise with BreatheMAX (6-10 beats/set, 10 set/day and rest between ste for 1 minute)
|
Before, during breathing exercise with device and immediate after treatment
|
|
Oxygen saturation (%SpO2)
Time Frame: Before, during breathing exercise with device and immediate after treatment
|
Oxygen saturation was monitored before, during and immediate after breathing exercise with BreatheMAX (6-10 beats/set, 10 set/day and rest between set for 1 minute)
|
Before, during breathing exercise with device and immediate after treatment
|
|
Respiratory rate (times/min)
Time Frame: In rest interval between set (1 minute)
|
Respiratory rate was measured by manual for 1 minute before, rest interval between set and immediate after breathing exercise with device (during the patients reconnection mechanical ventilation)
|
In rest interval between set (1 minute)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Sujittra Kluayhomthong, Bachelor, Physical Therapy department, Faculty of Associated Medical Sciences, Khon Kaen university
- Study Director: Chulee CU Jones, Philosophy, Physical Therapy Department, Faculty of Associated Medical Sciences, Khon Kaen university, Thailand
- Study Director: Wilaiwan Khrisanapant, Philosophy, Department of physiology, Faculty of medicine, Khon Kaen university
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
January 7, 2010
First Submitted That Met QC Criteria
March 22, 2010
First Posted (Estimate)
March 23, 2010
Study Record Updates
Last Update Posted (Estimate)
March 23, 2010
Last Update Submitted That Met QC Criteria
March 22, 2010
Last Verified
January 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 47660279
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Disease
-
Schön Klinik Berchtesgadener LandCompletedChronic Obstructive Lung Disease (n=10) | Interstitial Lung Disease (n=10)Germany
-
New Aera, IncUnknownInterstitial Lung Disease | Chronic Obstructive Lung Disease
-
Assistance Publique - Hôpitaux de ParisCompletedChronic Obstructive Lung Disease (COLD)France
-
Matthias GrieseTerminatedInterstitial Lung Disease | Diffuse Parenchymal Lung Disease | Children´s Interstitial Lung DiseaseGermany
-
Nuwacell Biotechnologies Co., Ltd.Not yet recruiting
-
PharmaLundensis ABCompletedChronic Obstructive Lung DiseaseSweden
-
Ruijin HospitalNot yet recruiting
-
Dai HuapingTongji Hospital; Shanghai Chest Hospital; The First Affiliated Hospital of Guangzhou... and other collaboratorsRecruitingInterstitial Lung Disease (ILD)China
-
University of AlbertaAlberta Boehringer Ingelheim CollaborationRecruitingFibrotic Interstitial Lung DiseaseCanada
-
Monash UniversityCompletedFibrotic Interstitial Lung DiseaseAustralia
Clinical Trials on BreatheMAX breathing device
-
Khon Kaen UniversityCompleted
-
Khajonsak PongpanitUnknownChronic Obstructive Pulmonary DiseaseThailand
-
Saikaew ChuachanKhon Kaen UniversityUnknownVentilatory DefectThailand
-
Khon Kaen UniversityCompletedBronchial Secretion RetentionThailand
-
Livotion, LLCNational Center for Complementary and Integrative Health (NCCIH); Purdue UniversityRecruiting
-
Syracuse UniversityCompleted
-
Khon Kaen UniversityUnknownPulmonary ComplicationsThailand
-
RehalerQmed Consulting A/STerminated
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Terminated
-
Miller, Chipp St. Kevin, M.D.UnknownSleep Apnea Syndromes | SnoringUnited States